Test tube structure for cancer risk assessment

Abstract

This invention discloses a reagent tube structure for cancer risk assessment, comprising a tube body and a cap. The cap is configured to cover the tube body. The tube body is configured to contain a plurality of antibodies, including anti-EpCAM antibody, anti-CSV antibody, and anti-CD45 antibody. The disclosed reagent tube structure for cancer risk assessment can be used in conjunction with flow cytometry to isolate circulating tumor cells from the blood of a subject for further cancer risk assessment.

Claims

1. A reagent tube structure for cancer risk assessment, comprising: One tube; and a top cover configured to cover the tube body; wherein the tube body is configured to contain a plurality of antibodies, the plurality of antibodies including a primary anti-EpCAM antibody, a primary anti-CSV antibody, and a primary anti-CD45 antibody.

2. The reagent tube structure for cancer risk assessment as described in claim 1, wherein, The anti-EpCAM antibody label has a first fluorescent label, the anti-CSV antibody label has a second fluorescent label, and the anti-CD45 antibody label has a third fluorescent label.

3. The reagent tube structure for cancer risk assessment as described in claim 1, wherein, The plurality of antibodies further includes a primary anti-PD-L1 antibody, a primary anti-eGFR antibody, a primary anti-MUC1 antibody, or a primary anti-CD44 antibody.

4. The reagent tube structure for cancer risk assessment as described in claim 1, wherein, The cancers mentioned are selected from the group consisting of adrenal cancer, breast cancer, ovarian cancer, endometrial cancer, cervical cancer, gallbladder cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, parathyroid cancer, prostate cancer, stomach cancer, testicular tumors, thyroid cancer, head and neck cancer, esophageal cancer, and bladder cancer.

5. The reagent tube structure for cancer risk assessment as described in claim 2, wherein, The first fluorescent marker, the second fluorescent marker, and the third fluorescent marker are three different markers.

6. The reagent tube structure for cancer risk assessment as described in claim 3, wherein, The anti-PD-L1 antibody, the anti-eGFR antibody, the anti-MUC1 antibody, and the anti-CD44 antibody are labeled with a first fluorescent label.

7. The reagent tube structure for cancer risk assessment as described in claim 1, wherein, The cancer risk assessment includes isolating a circulating tumor cell from a subject's blood through the reagent tube structure used for cancer risk assessment.

Images